FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3199580907> ?p ?o ?g. }

• W3199580907 abstract "Background: High concentrations of ivermectin demonstrated antiviral activity against SARS-CoV-2 in vitro.  Aim of this study was to assess safety and efficacy of high-dose ivermectin in reducing viral load in individuals with initial SARS-CoV-2 infection. Methods: Randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial performed in outpatients in Italy. Participants: adults recently diagnosed with asymptomatic/oligosymptomatic SARS-CoV-2 infection, providing informed consent. Exclusion criteria: pregnant or lactating women; CNS diseases; participants under dialysis; severe medical condition with  prognosis < 6 months; warfarin treatment; antiviral/chloroquine phosphate/hydroxychloroquine treatment. Participants were assigned according to a randomized permuted block procedure to one of the following arms with allocation ratio 1:1:1: placebo (arm A); single dose ivermectin 600 μg/kg plus placebo for 5 days (arm B); single dose ivermectin 1200 μg/kg for 5 days (arm C). The pharmacist prepared the treatment according to the randomization list and on the basis of the participant’s weight. Primary outcomes: serious adverse drug reactions (SADR) and change of viral load at Day 7. The protocol was registered with ClinicalTrials.gov , NCT04438850. Findings. From 31th July, 2020 to 26th May, 2021, 32 participants were randomized to arm A, 29 to arm B and 32 to arm C. The recruitment was stopped on 10th June, because of a dramatic drop of cases. Eighty-nine participants were included in the safety analysis set, the change in viral load was calculated on 87 participants. No SADR were registered. The mean log10 viral load reduction was 2.9 in arm C (SD 1.6), 2.5 (2.2) in arm B and 2.0 (2.1) in arm A, with no significant differences (p=0.099 and 0.122 for C versus A and B versus A, respectively). Interpretation: High- dose ivermectin demonstrated safe, but did not prove efficacy to reduce viral load.Trial Registration: The protocol was registered with ClinicalTrials.gov , NCT04438850. Funding: The trial was partly funded by the Italian Ministry of Health.Declaration of Interest: None to declare. Ethical Approval: This study was approved by the national Ethics Committee of INMI – Spallanzani in Rome that is competent for all COVID-19 trials in Italy (resolution 139/2020 of 28th May, 2020), and by the Italian drug agency AIFA (resolution 136BIS/2020 of 18th May, 2020)." @default.
• W3199580907 created "2021-09-27" @default.
• W3199580907 creator A5003500869 @default.
• W3199580907 creator A5007066407 @default.
• W3199580907 creator A5007796760 @default.
• W3199580907 creator A5008126184 @default.
• W3199580907 creator A5010578557 @default.
• W3199580907 creator A5010768270 @default.
• W3199580907 creator A5026604925 @default.
• W3199580907 creator A5028198430 @default.
• W3199580907 creator A5033263808 @default.
• W3199580907 creator A5044906620 @default.
• W3199580907 creator A5053162229 @default.
• W3199580907 creator A5053319055 @default.
• W3199580907 creator A5059583414 @default.
• W3199580907 creator A5060987368 @default.
• W3199580907 creator A5061332336 @default.
• W3199580907 creator A5062857031 @default.
• W3199580907 creator A5085123624 @default.
• W3199580907 creator A5087059862 @default.
• W3199580907 date "2021-01-01" @default.
• W3199580907 modified "2023-10-16" @default.
• W3199580907 title "High Dose Ivermectin for the Early Treatment of COVID-19 (COVIER Study): A Randomised, Double-Blind, Multicentre, Phase II, Dose-Finding, Proof of Concept Clinical Trial" @default.
• W3199580907 cites W1999067996 @default.
• W3199580907 cites W2012188043 @default.
• W3199580907 cites W2038618567 @default.
• W3199580907 cites W2120113475 @default.
• W3199580907 cites W2905465132 @default.
• W3199580907 cites W3014962324 @default.
• W3199580907 cites W3042647037 @default.
• W3199580907 cites W3118586278 @default.
• W3199580907 cites W3125712166 @default.
• W3199580907 cites W3159674227 @default.
• W3199580907 cites W3174504860 @default.
• W3199580907 doi "https://doi.org/10.2139/ssrn.3918289" @default.
• W3199580907 hasPublicationYear "2021" @default.
• W3199580907 type Work @default.
• W3199580907 sameAs 3199580907 @default.
• W3199580907 citedByCount "0" @default.
• W3199580907 crossrefType "journal-article" @default.
• W3199580907 hasAuthorship W3199580907A5003500869 @default.
• W3199580907 hasAuthorship W3199580907A5007066407 @default.
• W3199580907 hasAuthorship W3199580907A5007796760 @default.
• W3199580907 hasAuthorship W3199580907A5008126184 @default.
• W3199580907 hasAuthorship W3199580907A5010578557 @default.
• W3199580907 hasAuthorship W3199580907A5010768270 @default.
• W3199580907 hasAuthorship W3199580907A5026604925 @default.
• W3199580907 hasAuthorship W3199580907A5028198430 @default.
• W3199580907 hasAuthorship W3199580907A5033263808 @default.
• W3199580907 hasAuthorship W3199580907A5044906620 @default.
• W3199580907 hasAuthorship W3199580907A5053162229 @default.
• W3199580907 hasAuthorship W3199580907A5053319055 @default.
• W3199580907 hasAuthorship W3199580907A5059583414 @default.
• W3199580907 hasAuthorship W3199580907A5060987368 @default.
• W3199580907 hasAuthorship W3199580907A5061332336 @default.
• W3199580907 hasAuthorship W3199580907A5062857031 @default.
• W3199580907 hasAuthorship W3199580907A5085123624 @default.
• W3199580907 hasAuthorship W3199580907A5087059862 @default.
• W3199580907 hasConcept C126322002 @default.
• W3199580907 hasConcept C142724271 @default.
• W3199580907 hasConcept C204787440 @default.
• W3199580907 hasConcept C27081682 @default.
• W3199580907 hasConcept C2777499811 @default.
• W3199580907 hasConcept C2779134260 @default.
• W3199580907 hasConcept C2991744798 @default.
• W3199580907 hasConcept C3008058167 @default.
• W3199580907 hasConcept C42972112 @default.
• W3199580907 hasConcept C524204448 @default.
• W3199580907 hasConcept C535046627 @default.
• W3199580907 hasConcept C71924100 @default.
• W3199580907 hasConceptScore W3199580907C126322002 @default.
• W3199580907 hasConceptScore W3199580907C142724271 @default.
• W3199580907 hasConceptScore W3199580907C204787440 @default.
• W3199580907 hasConceptScore W3199580907C27081682 @default.
• W3199580907 hasConceptScore W3199580907C2777499811 @default.
• W3199580907 hasConceptScore W3199580907C2779134260 @default.
• W3199580907 hasConceptScore W3199580907C2991744798 @default.
• W3199580907 hasConceptScore W3199580907C3008058167 @default.
• W3199580907 hasConceptScore W3199580907C42972112 @default.
• W3199580907 hasConceptScore W3199580907C524204448 @default.
• W3199580907 hasConceptScore W3199580907C535046627 @default.
• W3199580907 hasConceptScore W3199580907C71924100 @default.
• W3199580907 hasLocation W31995809071 @default.
• W3199580907 hasOpenAccess W3199580907 @default.
• W3199580907 hasPrimaryLocation W31995809071 @default.
• W3199580907 hasRelatedWork W1533837487 @default.
• W3199580907 hasRelatedWork W1593330612 @default.
• W3199580907 hasRelatedWork W2255662531 @default.
• W3199580907 hasRelatedWork W2297531159 @default.
• W3199580907 hasRelatedWork W2414115992 @default.
• W3199580907 hasRelatedWork W3033863786 @default.
• W3199580907 hasRelatedWork W3123185276 @default.
• W3199580907 hasRelatedWork W3189393240 @default.
• W3199580907 hasRelatedWork W4254547722 @default.
• W3199580907 hasRelatedWork W4322617389 @default.
• W3199580907 isParatext "false" @default.
• W3199580907 isRetracted "false" @default.
• W3199580907 magId "3199580907" @default.
• W3199580907 workType "article" @default.